<?xml version='1.0' encoding='utf-8'?>
<document id="29901213"><sentence text="PBPK Modeling Strategy for Predicting Complex Drug Interactions of Letermovir as a Perpetrator in Support of Product Labeling." /><sentence text="Letermovir is a human cytomegalovirus (CMV) terminase inhibitor for the prophylaxis of CMV infection in allogeneic hematopoietic stem-cell transplant (HSCT) recipients" /><sentence text=" In vitro, letermovir is a time-dependent inhibitor and an inducer of cytochrome P450 (CYP)3A, and an inhibitor of CYP2C8 and organic anion transporting polypeptide (OATP)1B" /><sentence text=" A stepwise approach was taken to qualify the interaction model of an existing letermovir physiologically based pharmacokinetic model to predict letermovir interactions with CYP3A and OATP1B" /><sentence text=" The model was then used to prospectively predict the interaction between letermovir and CYP2C8 substrates such as repaglinide, a substrate of CYP2C8, CYP3A, and OATP1B"><entity charOffset="115-126" id="DDI-PubMed.29901213.s5.e0" text="repaglinide" /></sentence><sentence text=" The results showed that letermovir modestly increased the exposure of CYP2C8 substrates" /><sentence text=" These results were used to inform the US prescribing information in the absence of clinical drug-drug interaction studies" /><sentence text=" In addition, midazolam interactions with letermovir at therapeutic doses were also simulated to confirm that letermovir is a moderate CYP3A inhibitor"><entity charOffset="14-23" id="DDI-PubMed.29901213.s8.e0" text="midazolam" /></sentence><sentence text="" /></document>